- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.Fierce Biotech · 12d ago↗ source
- Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drugWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 12d ago↗ source
- Euro Roundup: EMA posts guidance on preventing microbial contamination of non-sterile productsThe European Medicines Agency (EMA) has released guidance on technical and organizational measures that companies should consider to prevent microbial contamination of non-sterile products.